Hansoh leads gains among HK-listed drugmakers on China's reimbursement list inclusion

Ascletis Pharma

03/12/2021 06:31

** Shares of Hansoh Pharmaceutical Group  3692.HK  jump
nearly 5% to HK$16.92, their biggest daily percentage gain since
Nov 10
    ** Stock on course for a second session of gains; is
second-biggest percentage gainer in Hang Seng China Enterprises
Index  .HSCE  
    ** The Jiangsu, China-based pharmaceutical group says its
"Tenofovir Amibufenamide Tablet" for treatment of chronic
hepatitis B virus infection has been included into the National
Reimbursement Drug List (NDRL)  urn:newsml:reuters.com:*:nFWN2SO02U
    ** Says the inclusion of the product into the NRDL will help
the company further enhance the affordability and accessibility
of the product among patients
    ** Analysts say inclusion in NRDL in China's state medical
insurance scheme potentially herald a massive leap in sales
    ** Shares of Ascletis Pharma  1672.HK  jump as much as 10.9%
in their best day since May 27, after co says its all-oral
direct anti-hepatitis C virus therapy - ASCLEVIR®/GANOVO®
regimen has been included in NDRL  urn:newsml:reuters.com:*:nFWN2SO02T
    ** Stock of Beigene  6160.HK  and HUTCHMED (China)  0013.HK 
narrow early losses to drop 1.1% and 0.3%, respectively, after
they announced that some of their products are included in NDRL
 urn:newsml:reuters.com:*:nFWN2SO05M urn:newsml:reuters.com:*:nFWN2SN19T
    ** Hong Kong's healthcare index  .HSCIH  climbs 0.3% 
    ** Hang Seng China Enterprises Index  .HSCE  slips 0.6% and
the benchmark index  .HSI  eases 0.1%

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))